Q-omics provides the consensus-scored RPL7AP7 profile across patient tissues and cancer cell-line models. RPL7AP7 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL7AP7 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RPL7AP7 RNA expression shows 6,298 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight CESC, and KIRC as cancer lineages where RPL7AP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP7 survival associations across molecular data types. RPL7AP7 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP7 RNA expression–survival associations across cancer types. High RPL7AP7 expression shows unfavorable associations in KIRP, THYM, THCA, PAAD and ACC, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for RPL7AP7 RNA expression.
This table summarizes RPL7AP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP7 shows higher tumor expression in KIRC, HNSC, COAD, THCA, LUAD and LUSC. The KIRC box plot shows higher RPL7AP7 RNA expression in tumor versus normal tissue (log2 FC = +0.502, t-test p < 0.001).
This table shows molecular features associated with RPL7AP7 in patient tissues and cancer cell lines. In patient samples, RPL7AP7 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
